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Detection of EGFR Mutation Status in Lung
Adenocarcinoma Specimens with Different Proportions of
Tumor Cells Using Two Methods of Differential Sensitivity
Hye-Suk Han, MD,* Sung-nam Lim, MD,* Jin Young An, MD,* Ki Man Lee, MD,*
Kang Hyeon Choe, MD,* Ki Hyeong Lee, MD,* Seung Taik Kim, MD,* Seung-Myoung Son, MD,†
Song-Yi Choi, MD,† Ho-chang Lee, MD,† and Ok-Jun Lee, MD†
Introduction: To evaluate epidermal growth factor receptor
(EGFR) mutation status in lung adenocarcinoma specimens with
different proportions of tumor cells using two methods with differ-
ent sensitivities.
Methods: EGFR mutation status was determined by peptide nucleic
acid (PNA) clamping and direct sequencing. The samples consisted
of 41 cell blocks of malignant pleural effusions with various pro-
portions of tumor cells, as well as 23 lung biopsy specimens
containing more than 20% tumor cells and the corresponding sur-
gically resected tumors.
Results: In the analysis of malignant pleural effusions, EGFR
mutations were detected only by PNA clamping in four of nine
patients who exhibited partial response to EGFR tyrosine kinase
inhibitors; all the cell blocks of these four patients contained less
than 20% tumor cells. Direct sequencing revealed wild-type EGFR,
whereas PNA clamping revealed mutant EGFR, in one of five
patients who exhibited progressive disease in response to EGFR
tyrosine kinase inhibitor; the cell block of this patient contained a
high proportion of tumor cells. A comparison of biopsy specimens
containing sufficient tumor cells and the corresponding surgically
resected tumors revealed discordance in the EGFR mutation status
in four patients based on PNA clamping, whereas no discrepancies
were observed by direct sequencing.
Conclusions: Highly sensitive methods, such as PNA clamping,
may be superior to direct sequencing for the detection of EGFR
mutations in diagnostic specimens with a low proportion of tumor
cells. Direct sequencing may be more representative when diagnos-
tic specimens with a high proportion of tumor cells are available.
Key Words: Direct sequencing, Epidermal growth factor receptor
mutation, Lung adenocarcinoma, PNA clamping, Sensitivity.
(J Thorac Oncol. 2012;7: 355–364)
The epidermal growth factor receptor (EGFR) gene en-codes a widely expressed transmembrane receptor protein
that has been implicated in the development and progression
of cancer.1 The observation that non-small cell lung cancer
(NSCLC) cells frequently express EGFR2–4 has raised the
level of interest in clinical trials of EGFR tyrosine kinase
inhibitors (TKIs) such as gefitinib (Iressa; AstraZeneca, Wil-
mington, DE) and erlotinib (Tarceva; OSI Pharmaceuticals,
Melville, NY).5–11 Somatic mutations in the region of EGFR
that encodes the tyrosine kinase domain of the receptor
(exons 18–21) have been identified in NSCLC, and many
studies have reported that NSCLC with these mutations is
highly responsive to EGFR TKIs.6–11 As such, the EGFR
mutation status of NSCLC is used to help guide treatment
decisions and/or to determine eligibility for clinical trials.
Direct sequencing is used routinely for the detection of
EGFR mutations. However, the sensitivity of direct sequenc-
ing is suboptimal for many clinical tumor samples; mutant
DNA must comprise 25% of the total DNA to be readily
detected.12,13 However, available samples for mutational
analysis in lung cancer are often limited to small tissue
biopsies or cytologic specimens. Moreover, clinical samples
that are used to diagnose lung cancer typically contain a high
proportion of normal cells in addition to cancer cells. These
considerations continue to drive the development and evalu-
ation of different techniques for detecting EGFR mutations.
Recently, highly sensitive methods including the scorpion
amplified refractory mutation system, mutant-enriched poly-
merase chain reaction (PCR), LightCycle PCR with Taqman-
MGB probes, and peptide nucleic acid (PNA) clamping have
been developed.12,13–21 These assays are more sensitive than
direct sequencing and detect mutations against a 100- to
1000-fold higher background level of wild-type alleles. With
these methods, EGFR mutations are readily detectable in
various clinical samples; thus, they could potentially be
integrated into routine clinical practice for molecular charac-
terization of NSCLC.
In this study, the EGFR mutation statuses of various
clinical samples from patients with lung adenocarcinoma
were evaluated by two methods with different sensitivities:
PNA-mediated real-time PCR clamping and direct sequenc-
ing. On the basis of the differences observed between the two
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methods in terms of determining EGFR mutation status, we
assessed which method is most appropriate for a given





To confirm the sensitivities of PNA clamping and direct
sequencing, three different cell lines were used, including one
carrying wild-type EGFR (A549) and two carrying mutations
in EGFR (PC9 and H1975). Wild-type cells were mixed with
mutant cell lines in varying proportions. All cell lines were
established from NSCLCs. The A549 and H1975 cell lines
were obtained from American Type of Culture Collection
(Rockville, MD). The PC9 cell line was obtained from the
Konkuk University Medical Center (Seoul, Korea). PC9 cells
carry a Glu746-Ala750 deletion mutation in exon 19 of the
EGFR gene, and H1975 cells carry two point mutations,
T790M and L858R, in exons 20 and 21, respectively.
Cell Blocks of Malignant Pleural Effusions
Cases were reviewed by using a pathological database
of patients who had undergone tapping of pleural effusions
and who had been diagnosed with lung adenocarcinoma at
Chungbuk National University Hospital between January
2006 and December 2010. Pathologically confirmed, ethanol-
fixed, and paraffin-embedded cell blocks of pleural effusions
obtained from patients with lung adenocarcinoma were in-
cluded. The percentage of tumor cells in the cell block of
each malignant pleural effusion (MPE) was determined inde-
pendently by two pathologists, and the average was taken.
The EGFR mutation status was evaluated on the basis of the
tumor cell percentage in the cell blocks.
Adequate Lung Biopsy Specimens at Diagnosis and
Corresponding Surgically Resected Tumors
To evaluate the most appropriate detection method for
EGFRmutations in samples containing a sufficient number of
tumor cells, a pathological database of lung adenocarcinoma
patients who had undergone lung biopsy at initial diagnosis
and later underwent surgical resection at Chungbuk National
University Hospital between January 2007 and January 2011
was consulted. Formalin-fixed, paraffin-embedded biopsy
specimens of lung adenocarcinoma containing more than
20% tumor cells and the corresponding matched surgically
resected tumor tissues were used.
DNA Isolation
Cell lines
Cell lines were expanded in RPMI-1640 medium con-
taining 10% (vol/vol) fetal calf serum and were cultured
according to standard procedures. Genomic DNA was pre-
pared with a High Pure PCR Template Preparation Kit
(Roche Applied Science, Mannheim, Germany) and quanti-
fied with a NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies, Wilmington, DE). The DNA was stored
at 20°C until use.
Tumor Samples
DNA was extracted from five paraffin sections (10 m)
representative of the cell blocks and tumor tissue. Before
DNA isolation, the tissue was deparaffinized in xylene and
then washed in 70% ethanol. DNA was isolated with a High
Pure PCR Template Preparation Kit (Roche Applied Science)
according to the manufacturer’s protocol. The DNA obtained
was eluted in 50 l of elution buffer, and the concentration
and purity of the extracted DNA were assessed by spectros-
copy with a NanoDrop ND-1000 spectrophotometer (Nano-
Drop Technologies). The average DNA yield from the tumor
samples was 100 ng. The extracted DNA was stored at
20°C until use.
PNA Clamping
The EGFR mutation status of extracted DNA from cell
lines and tumor samples was determined with the PNAClamp
EGFR Mutation Detection Kit (Panagene, Inc., Daejeon,
Korea). The assay, based on PNA clamping technology,
quickly and accurately detects specific mutations or deletions
at known positions of the EGFR gene.15,16 PNA is a synthetic
DNA analog in which the phosphodiester backbone is re-
placed by a peptide-like repeat formed by (2-aminoethyl)-
glycine units. Because PNA contains no charged phosphate
groups, the binding between the PNA probe and target DNA
is stronger than that between a DNA probe and target DNA,
because of the lack of electrostatic repulsion. In addition,
PNA is resistant to DNases and proteases and is stable across
a wide range of pH. The PNAClamp EGFR Mutation Detec-
tion Kit is schematically shown in Figure 1. PNA probes and
DNA primers are used together in the clamping reaction.
Positive signals are detected by intercalation of SYBR Green
fluorescent dye. The PNA probe suppresses the amplification
of the wild-type sequence, thereby enhancing preferential
amplification of the mutant sequences by competitively in-
hibiting the binding of DNA primer to wild-type DNA. Thus,
FIGURE 1. The peptide nucleic acid (PNA) clamping sys-
tem. The PNA oligomer was designed to bind to the bottom
strand of the wild-type sequence, spanning mutational hot-
spots in exons 18–21 of the epidermal growth factor recep-
tor gene. The forward polymerase chain reaction (PCR)
primer partially overlapped the PNA binding site. A, A PNA/
DNA hybrid with a perfect match prevents annealing of the
PCR primer and amplification of wild-type DNA. B, A PNA/
DNA hybrid with a single base pair mismatch does not sup-
press annealing of the PCR primer or amplification of mutant
alleles.
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individual EGFRmutations can be detected in the presence of
a 100- to 1000-fold higher level of background wild-type
sequence. All reactions were carried out in a volume of 20 l
with template DNA, a primer and PNA probe set, and SYBR
Green PCR master mix. All reagents are included in the kit.
Real-time PCR was performed with a CFX 96 (Bio-Rad,
Philadelphia, PA). The thermocycling conditions were as
follows: 5 minutes at 94°C followed by 40 cycles of 94°C for
30 seconds, 70°C for 20 seconds, 63°C for 30 seconds, and
then 72°C for 30 seconds. Detection of each of 29 mutations
in the EGFR gene was possible with the PNAClamp EGFR
Mutation Detection kit.
PCR efficiency was determined by evaluating threshold
cycle (Ct) values. The Ct was automatically calculated from
PCR amplification plots of SYBR Green fluorescence versus
the number of cycles. The PNAClamp method contains a
negative control (wild-type DNA control) that helps to mon-
itor potential contamination. The Ct value of the wild-type
DNA control (standard Ct value) should fall within a given
acceptable Ct range. The Ct value of the non-PNA mix must
be less than 30 to ensure successful amplification. Delta Ct
(Ct) was calculated to ensure that the sample and standard
Ct values were from the tested sample and wild-type DNA
control sample:
Ct [Standard Ct] [Sample Ct]
When the Ct  1 value (the standard Ct value minus Ct
value of the target specimen) is more than 2.0, the specimen
is presumed to be mutated. When the Ct  1 value is
between 0 and 2, the Ct  2 value (Ct value of the target
specimen minus Ct value of the non-PNA mix) is calculated.
If this value is less than 3, then the specimen is presumed to
be mutated.
Direct Sequencing
PCRs were performed in a final volume of 25 l
containing 1 PCR buffer, 200 nM dNTPs, 10 pmol/l each
primer, 0.75 U Taq polymerase (Solgent, Daejeon, Korea),
and 50 ng of genomic DNA. Exons 18–21 of EGFR were
sequentially amplified by two rounds of PCR. The amplified
products were subjected to direct sequence analysis. PCR
cycling commenced with a 5-minute incubation at 94°C,
followed by 40 cycles of 94°C for 30 seconds, 63°C for 30
seconds, 72°C for 30 seconds, and then a final incubation
at 72°C for 10 minutes. The amplified products were
purified with a PCR clean-up kit (Macherey-Nagel, Ger-
many) and were sequenced in duplicate in the forward and
reverse directions with a BigDye Terminator Kit (Applied
Biosystems, Forster City, CA) and an ABI Prism 3100
DNA analyzer (Applied Biosystems) according to the
manufacturer’s instructions. Sequences were compared
with the archived sequence of human EGFR found in
GenBank (http://www.ncbi.nlm.nih.gov).
Clinicopathological characteristics, including age, sex,
smoking history, and treatment, were obtained from medical
records. This study was reviewed and approved by the Insti-
tutional Review Board of Chungbuk National University
Hospital.
RESULTS
Sensitivities of PNA Clamping and Direct
Sequencing for Detecting EGFR Mutations
For the analysis of exons 19–21, the proportion of
mutant (PC9- and H1975-derived) DNA to wild-type (A549-
derived) DNA was adjusted to 50%, 30%, 20%, 10%, 5%,
1%, and 0% to reflect the different proportions of wild-type
and mutant DNA in tumor samples. PNA clamping detected
individual EGFR mutations in the presence of up to 100-fold
excess of wild-type EGFR DNA. However, direct sequencing
for EGFR mutations did not exhibit such sensitivity; as is
already known, it could only detect individual EGFR muta-
tions in cell line mixtures comprising more than 20% mutant
tumor cells. The EGFR mutation statuses of mixtures of lung
adenocarcinoma cells according to proportion of each EGFR
mutation type are summarized in Table 1.
EGFR Mutation Status in Cell Blocks of MPEs
A total of 41 cell blocks of MPEs from patients diag-
nosed with lung adenocarcinoma were analyzed by PNA
TABLE 1. EGFR Mutation Status in Lung Adenocarcinoma Cell Lines According to the Proportion of EGFR Mutation Type
EGFR Mutation











100 0 0 0 0 0 Negative Negative Negative
98 1 1 4.19 4.12 3.11 Negative Negative Negative
90 5 5 6.44 5.82 3.78 Negative Negative Negative
80 10 10 7.38 6.98 5.51 Negative Negative Negative
60 20 20 8.51 7.64 6.42 Positive Positive Positive
40 30 30 9.23 8.57 8.54 Positive Positive Positive
45 50 5 10.00 6.00 5.91 Positive Negative Negative
45 5 50 6.40 9.30 9.11 Negative Positive Positive
The cutoff Ct was defined as 2 for the EGFR mutation.
EGFR, epidermal growth factor receptor; PNA, peptide nucleic acid; Ct, threshold cycle; Ct, standard Ct  sample Ct.
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clamping and direct sequencing. The EGFR mutation status
in MPEs for each patient is shown in Table 2. The cell blocks
of MPEs were divided into two groups, based on the sensi-
tivity of the direct sequencing in the cell line mixtures: a
group with a low tumor cell percentage (20%) and a group
with a high tumor cell percentage (20%). Seventeen of the
cell blocks (41.5%) contained a low (20%) proportion of
tumor cells. Thirteen (31.7%) patients were women and had
never smoked. Seventeen patients (41.5%) were treated with
EGFR TKIs (gefitinib or erlotinib) as a second-line or further
therapy during the course of the disease, and 14 of these 17
patients were assessed for responses.
TABLE 2. Patient Characteristics and EGFR Mutation Status of Cell Blocks of Malignant Pleural Effusions Determined by PNA
Clamping and Direct Sequencing
Proportion of
Tumor Cells (%) Case Sex Age (yr)
Smoking
History
EGFR Mutation EGFR TKI
PNA Clamping Direct Sequencing Use Response
Low
10 1 F 55 Never WT WT Yes NA
2 M 66 Active L858R or L861Q WT Yes PR
3 M 60 Active L858R or L861Q WT No
4 M 67 Former WT WT No
5 F 63 Never WT WT Yes PD
6 M 82 Former WT WT No
7 M 62 Former WT WT No
8 F 71 Never L858R or L861Q WT Yes PR
9 F 69 Never L858R or L861Q WT Yes PR
10 M 67 Active WT WT Yes PR
11 M 34 Never WT WT No
10–19 12 M 77 Former WT WT No
13 F 39 Never WT WT No
14 M 60 Active WT WT Yes PD
15 F 65 Never L858R or L861Q WT Yes PR
16 F 68 Former Exon 19 del 2235–2249 del Yes PR
17 M 58 Active L858R or L861Q WT No
High
20–29 18 M 70 Unknown WT WT No
19 F 41 Never L858R or L861Q L858R Yes PR
20 M 69 Active WT WT No
21 M 67 Active WT WT No
30–39 22 M 48 Active WT WT Yes PD
23 M 66 Active WT WT No
24 F 75 Never WT WT Yes NA
25 F 79 Never WT WT No
40–49 26 M 91 Former WT WT No
27 M 71 Unknown WT WT No
28 M 71 Active WT WT Yes PD
29 M 79 Active WT WT No
50–59 30 M 62 Active L858R or L861Q WT No
31 M 59 Active Exon 19 del 2240–2257 del No
60–69 32 M 75 Active L858R or L861Q WT Yes PD
33 M 75 Active WT WT No
34 M 73 Active L858R or L861Q L858R Yes PR
70 35 M 44 Active Exon 19 del WT No
36 M 45 Active WT WT No
37 M 78 Active Exon 19 del WT No
38 F 80 Never Exon 19 del 2236–2250 del Yes PR
39 F 81 Never Exon 19 del 2240–2254 del No
40 M 61 Active WT WT Yes NA
41 F 85 Never WT WT No
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; PNA, peptide nucleic acid; WT, wild type; PR, partial response; SD, stable disease; PD, progressive
disease; NA, not available.
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The EGFR mutation was detected in cell blocks from
16 (39.0%) of 41 patients by PNA clamping. The mutations
included 6 in-frame deletions in exon 19 and 10 point mutations
(L858R or L861Q) in exon 21. By contrast, the EGFR mutation
was detected in only 6 (14.6%) of the 41 patients by direct
sequencing, including 4 in-frame deletions in exon 19 and 2
point mutations (L858R) in exon 21. Thus, PNA clamping
detected 10 cases with EGFR mutations that were not detected
by direct sequencing. In addition, PNA clamping tended to be
more sensitive in cell blocks containing a low proportion of tumor
cells.
Of the 14 patients who were treated with EGFR TKIs
and were assessed for responses, nine (64.3%) achieved a
partial response and five (35.7%) experienced progressive
disease. In four of the nine patients who experienced a
partial response to EGFR TKIs, EGFR mutations were
detected by both PNA clamping and direct sequencing. In
four of the remaining five patients (cases 2, 8, 9, and 15),
EGFR mutations were detected only by PNA clamping; all
the cell blocks of these latter four patients contained a low
proportion of tumor cells. The remaining patient (case 10)
who achieved a partial response did not show evidence of
FIGURE 2. Representative histology, epidermal growth factor receptor (EGFR) mutation status, and response to EGFR
tyrosine kinase inhibitors (TKIs) for two patients (cases 9[A] and 32[B]) carrying an EGFR mutation that was detected only
by peptide nucleic acid (PNA) clamping, but who responded differently to EGFR TKI therapy, and whose tumors con-
tained different proportions of tumor cells. A, Tumor cells in the cell block of the malignant pleural effusion represented
10% of all nucleated cells (hematoxylin and eosin [H&E]; original magnification, 400). EGFR status detected by PNA
clamping indicated the presence of a leucine to arginine mutation (L858R) in exon 21, whereas direct sequencing indi-
cated a wild-type allele. The objective response to EGFR TKI therapy was partial response. B, Tumor cells in the cell block
of the malignant pleural effusion represented 50% of all nucleated cells (H&E; original magnification, 400). EGFR sta-
tus detected by PNA clamping indicated an L858R mutation in exon 21, whereas direct sequencing indicated a wild-type
allele. However, the objective response to EGFR TKI therapy was progressive disease. (a) A cell block of malignant pleural
effusion (H&E), (b) amplification curve derived from PNA clamping, (c) direct sequencing chromatograms, (d) response
to EGFR TKI therapy.
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an EGFR mutation by either technique. Four of the five
patients who experienced progressive disease with EGFR
TKI therapy carried wild-type EGFR, as detected by both
PNA clamping and direct sequencing. For the remaining
patient (case 32), wild-type EGFR was detected only by
direct sequencing; the cell block of this patient contained
a high proportion of tumor cells. Figure 2 shows the
representative cell blocks of cases 9 and 32, in which the
EGFR mutation was detected only by PNA clamping,
which exhibited different responses to EGFR TKIs and had
different proportions of tumor cells.
EGFR Mutation Status in Adequate Lung
Biopsies and Corresponding Surgically
Resected Specimens
A total of 23 adequate lung biopsy specimens contain-
ing more than 20% tumor cells and corresponding surgically
resected lung adenocarcinomas were analyzed by PNA
clamping and direct sequencing. The results for each patient
are shown in Table 3. EGFR mutation status by PNA clamp-
ing was detected in the biopsy specimens of 16 (69.6%)
patients and in the surgically resected specimens of 12
FIGURE 2. (Continued).
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(52.2%) patients. This corresponded to a discordance rate of
17.4% (4 of 23 patients) between biopsy specimens and the
corresponding surgically resected specimens. By direct se-
quencing, the EGFR mutation was detected in 12 adequate
biopsy specimens (52.2%) and all the 12 matched surgically
resected tumor specimens. Thus, there were no discrepancies
between mutation status in biopsy specimens and correspond-
ing surgically resected specimens based on direct sequencing.
In surgically resected tumors, the EGFR mutation status was
the same irrespective of the method used.
DISCUSSION
Recent advances in biotechnology have enabled the
development of more sensitive methods than direct sequenc-
ing for the detection of DNA mutations, and unique ap-
proaches to detecting EGFR mutations with high sensitivity
have been described.12,13–21 PNA clamping is one such tech-
nique. In this study, PNA clamping technology using a
PNAClamp EGFR Mutation Detection Kit detected EGFR
mutations in cell line mixtures in the presence of a 100-fold
excess of wild-type cells. The results of previous studies have
shown that such sensitive methods for the detection of EGFR
mutations improve detection rates compared with conven-
tional direct sequencing in clinical samples such as pleural
fluid, cytologic specimens (e.g., needle aspirates, sputum,
bronchial washing or brushing), and plasma.14,17–20,22,23 In the
current analysis of MPEs, PNA clamping detected EGFR
mutations in 10 samples that were missed by direct sequenc-
ing. Thus, the rate of detection by the two methods differed
significantly (39.0% versus 14.6%, respectively). These re-
sults confirm the notion that PNA clamping is a rapid and
highly sensitive method for the detection of EGFR mutations
in clinical samples from patients with lung cancer, although it
can only be used to detect mutations for which primers have
been individually designed.
EGFR mutations may accumulate during tumor pro-
gression, leading to the heterogeneity of EGFR status within
a tumor. The presence of multiple EGFR mutations in a
single tumor specimen has been reported in a number of
studies.24–27 This heterogeneity of EGFR mutations could
partially account for the fact that some patients with wild-
type EGFR responded to EGFR TKIs, and some patients with
TABLE 3. EGFR Mutation Status in Adequate Biopsies and the Corresponding Surgically Resected Specimens of Lung
Adenocarcinoma as Determined by PNA Clamping and Direct Sequencing
Case Sex Age (yr)
EGFR Mutation Status









1 M 48 Exon 19 del Exon 19 del 1924 del 1923 del
2 M 65 Exon 19 del Exon 19 del 1918 del 1918 del
3 F 72 Exon 19 del Exon 19 del 1924 del 1924 del
4 F 40 Exon 19 del WT WT WT
5 F 65 Exon 19 del Exon 19 del 1934 del 1934 del
6 M 58 Exon 19 del Exon 19 del 1923 del 1923 del
7 F 63 WT WT WT WT
8 M 70 Exon 19 del Exon 19 del 1918 del 1918 del
9 M 58 Exon 19 del WT WT WT
10 M 73 WT WT WT WT
11 M 73 Exon 19 del/L858R
or L861Q
L858R or L861Q L858R L858R
12 F 53 Exon 19 del Exon 19 del 1924 del 1924 del
13 M 67 Exon 19 del/L858R
or L861Q
WT WT WT
14 M 73 WT WT WT WT
15 M 67 WT WT WT WT
16 F 51 WT WT WT WT
17 M 65 Exon 20 Ins. 3 dup Exon 20 Ins. 3 dup del 2015 del 2015
18 M 50 L858R or L861Q L858R or L861Q L858R L858R
19 F 72 Exon 19 del Exon 19 del 1918 del 1918 del
20 F 63 Exon 19 del/exon
20 Ins. 3 dup
Exon 19 del 1918 del/2015 del 1918 del
21 M 49 WT WT WT WT
22 M 79 WT WT WT WT
23 M 68 Exon 19 del/L858R
or L861Q
WT WT WT
Adequate biopsy specimen was defined as biopsy tissue of lung adenocarcinoma containing 20% of tumor cells.
EGFR, epidermal growth factor receptor; PNA, peptide nucleic acid; WT, wild type.
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an EGFR mutation failed to respond to EGFR TKIs. How-
ever, Yatabe et al.,28 recently reported that the heterogeneous
distribution of EGFR mutations is extremely rare in lung
adenocarcinomas, unlike many prior studies on the heteroge-
neity of EGFR mutations. They suggested that a potential
explanation for the heterogeneous distribution of EGFR mu-
tations is the presence of “pseudoheterogeneity” caused by
mutant-allele specific imbalance and heterogeneously distrib-
uted EGFR amplification. Many clinicians are often faced
with the heterogeneous distribution of EGFR mutation status
within a tumor or between primary and matched metastatic
tumors, even if this phenomenon results from pseudohetero-
geneity. The clinical implications of the difference between
true heterogeneity and pseudoheterogeneity are unknown;
therefore, further studies about comparisons of the two kinds
of EGFR genetic alterations and their relationship to response
to EGFR TKIs are needed. When starting this study, we
assumed that EGFRmutation heterogeneity is not rare in lung
FIGURE 3. Schema showing ap-
propriate use of different methods
for the detection of epidermal
growth factor receptor (EGFR) mu-
tation status, depending on the
proportion of tumor cells in lung
adenocarcinoma samples. A, In
clinical samples with a low propor-
tion of tumor cells (10%), a highly
sensitive method may be useful.
Clinical samples were representa-
tive in four patients (cases 2, 8, 9,
and 15) who experienced a partial
response to EGFR tyrosine kinase
inhibitor (TKI) therapy and whose
EGFR mutant status was detected
only by peptide nucleic acid clamp-
ing. B, On the other hand, for clini-
cal samples with a high proportion
of tumor cells (50%), EGFR muta-
tion status by direct sequencing
may be more representative of the
whole tumor. One patient (case
32) experienced progressive disease
on treatment with EGFR TKI, and
EGFR wild-type status was detected
only by direct sequencing. MT-tu-
mor cell, mutant-type tumor cell;
WT-tumor cell, wild-type tumor
cell.
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adenocarcinoma; if this assumption is correct, then the re-
sponse to EGFR TKIs may be related to the proportion of
mutated tissues or cells. Taniguchi et al.24 reported that the
time to progression and overall survival after gefitinib treat-
ment in patients with EGFR mutation heterogeneity was
significantly shorter than for patients who did not exhibit
EGFR heterogeneity. When considering intratumoral hetero-
geneity, an important factor is the overall EGFR status of the
cancer tissue; in other words, it is important that the clinical
samples available are representative of the whole tumor.
When we analyzed mutational status based on clinical re-
sponse to EGFR TKIs, in four patients (cases 2, 8, 9, and 15)
who achieved a partial response, direct sequencing suggested
wild-type status, whereas PNA clamping suggested EGFR
mutant status. In another case (case 32), direct sequencing
indicated a wild-type EGFR status, and PNA clamping indi-
cated EGFR mutant status, but this patient experienced dis-
ease progression in response to EGFR TKI therapy. Interest-
ingly, the proportion of tumor cells in cell blocks of MPEs for
the four patients who achieved a partial response was less
than 20%, whereas for one patient who experienced disease
progression, the proportion was 65%. Although we cannot
state a firm conclusion, because of the small cohort numbers,
these results suggest that, for clinical samples containing a
low proportion of tumor cells, PNA clamping is a better,
more representative, and sensitive method of determining
EGFR status than direct sequencing. On the other hand, PNA
clamping may be less representative for samples that contain
a high proportion of tumor cells, as it may detect EGFR
mutations present in a minor proportion of cells (Figure 3).
The results of our analysis of lung adenocarcinoma biopsy
specimens shed some light on this issue. We compared the
EGFRmutation status in biopsy specimens from patients with
lung adenocarcinoma, which contained a high proportion of
tumor cells (20%), and the corresponding surgically re-
sected tumors obtained from the same patients after the
diagnosis of lung adenocarcinoma by biopsy. In four cases,
PNA clamping indicated wild-type EGFR in the surgically
resected specimen, but mutant-type EGFR mutation status in
the corresponding biopsy specimen, with a discordance rate
of 17.4%. On the other hand, using direct sequencing, we
obtained identical results for 12 biopsy specimens and the
corresponding surgically resected tumor tissues. Thus, for
clinical samples with a high proportion of tumor cells, direct
sequencing provided an EGFR mutation status that was more
consistent and more representative of the whole tumor.
Although this study was conducted on a relatively small
number of cases, our results suggest that more than one
method may be required for the screening of different types
of clinical samples of lung adenocarcinoma for EGFR muta-
tions. These two methods of detecting EGFR mutation are
complementary for the analysis of various clinical samples in
lung adenocarcinoma. The interpretation of EGFR mutation
status should consider not only the sensitivity of the method
used but also the proportion of tumor cells in the diagnostic
sample. Further studies are needed to confirm these results
and to determine whether differences in EGFR mutation
status detected using methods with different sensitivities are
associated with treatment response to EGFR TKIs in lung
adenocarcinoma.
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